Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma ADR (NQ: ASND )

91.74 -0.47 (-0.51%)
Streaming Delayed Price Updated: 1:13 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 37,273
Open 92.21
Bid (Size) 91.69 (2)
Ask (Size) 91.79 (1)
Prev. Close 92.21
Today's Range 91.50 - 92.94
52wk Range 64.33 - 134.53
Shares Outstanding 57,152,295
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Latest Analyst Ratings for Ascendis Pharma
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga

Performance

YTD
-24.01%
-24.01%
1 Month
-5.62%
-5.62%
3 Month
-15.67%
-15.67%
6 Month
-23.20%
-23.20%
1 Year
+0.59%
+0.59%

More News

Read More
FDA Rejects Ascendis Pharma's TransCon PTH For Hypoparathyroidism
Via Benzinga
Why Shares of Ascendis Pharma Are Climbing Monday
Via The Motley Fool
US Stocks Rise; Norwegian Cruise Line Posts Q1 Results
Via Benzinga
IVERIC bio, Ascendis Pharma And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Via Benzinga
Why Ascendis Pharma Stock Is Crashing This Week
Via The Motley Fool
Analyst Ratings for Ascendis Pharma
Via Benzinga
Why Ascendis Pharma Stock Is Plunging Today
Via The Motley Fool
Bragar Eagel & Squire, P.C. Is Investigating Fox, Ascendis, and Shift4 and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Hedge Funds Fall Short: Underperforming Low-Cost S&P 500 ETF By 6% In 2023. Here's Why.
Via Benzinga
NASDAQ: ASND Shareholder Notice: Investigation over Possible Securities Laws Violations by Ascendis Pharma A/S
Via SBWire
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation - ASND
Via NewMediaWire
Exposures Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
ASCENDIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ascendis Pharma A/S on Behalf of Ascendis Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2023
Via Benzinga
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ascendis Pharma A/S (ASND) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Nasdaq Down 80 Points; VirTra Shares Spike Higher
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Up Triple Digits As Second Quarter Kicks Off
Via Talk Markets
Why Heska Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Crude Oil Jumps Over 6%; OncoSec Medical Shares Plummet
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.